ArticleTransplant infectious disease : an official journal of the Transplantation Society
Real-World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus-Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe objective of this study was to analyze outcomes associated with letermovir for CMV primary prophylaxis in adult CMV-seropositive allo-HCT recipients in a multicenter real-world scenario.
methodsThis retrospective real-world international study involved 481 adults undergoing allo-HCT between 2018 and 2020 who received letermovir for primary prophylaxis. Outcomes included clinically significant CMV infection (csCMVi), graft-versus-host disease, opportunistic infections, all-cause mortality, hospitalizations, and ICU admissions. The median follow-up was 33.8 months.
resultsThe median start time of letermovir was 3 days after transplant, with a median duration of prophylaxis of 100 days. The cumulative incidence of csCMVi was 2.7% (95% CI = 1.5-4.5) at 3 months, 13.1% (95% CI = 10.3-16.3) at 6 months, and 17.1% (95% CI = 13.9-20.6) at 12 months. The median time from HCT to csCMVi was 142 days. In multivariate analysis, four factors contributed to development of csCMVi: reduced-intensity conditioning (HR = 1.90; 95% CI = 1.17-3.08; p = 0.009), peripheral blood as cell source (HR = 2.92; 95% CI = 1.00-8.50; p = 0.0495), pretransplant CMV serostatus D-/R+ (HR = 2.24; 95% CI = 1.42-3.53; p = 0.0005), use of alemtuzumab (HR = 3.91; 95% CI = 1.60-9.59; p = 0.003). There was no difference in the cumulative incidence of csCMVi in the first 100 days between patients who started letermovir ≤ 5 versus > 5 days after transplant. Factors adversely contributing to overall survival: age as a continuous variable, 10-year effect (HR = 1.23; 95% CI = 1.08-1.41; p = 0.002), patient male sex (HR = 1.48; 95% CI = 1.02-2.13; p = 0.038), status > CR1 of disease at transplant (HR = 1.97; 95% CI = 1.36-2.85; p = 0.0004), PB as stem cell source (HR = 1.81; 95% CI = 1.04-3.15; p = 0.04), acute leukemia diagnosis (HR = 1.61; 95% CI = 1.10-2.34; p = 0.01), CMV high-risk patients (HR = 1.52; 95% CI = 1.02-2.27; p = 0.04).
conclusionsAn analysis of real-world use of letermovir in CMV prophylaxis after allo-HCT showed a low incidence of csCMVi compared to previously published information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.